Med24
overweight-obesity 23. 9. 2026 • 2 min read • Frontiers in nutrition

Beyond body mass index: phenotypic and circulating biomarkers for the identification and characterization of sarcopenic obesity

Sarcopenic obesity (SO), the coexistence of excess adiposity with low skeletal muscle mass and function, is a growing but frequently underdiagnosed condition associated with physical disability, cardiometabolic disease, and increased mortality. Its recognition is hampered by an over-reliance on body mass index, which...

Addressing Post-Intensive Care Syndrome Among Survivors of COVID (APICS-COVID)

Sarcopenic obesity (SO), a combination of excess fat and reduced muscle mass, is often missed due to reliance on body mass index. Current diagnostic methods frequently identify SO only after functional impairment develops.

Phenotypic Marker Assessment

Research explores using advanced imaging and molecular biology to detect early signs of the condition. The review examines phenotypic markers, including myosteatosis measured by computed tomography and the bioelectrical phase angle, assessing both muscle quantity and quality. It also investigates circulating biomarkers such as myokines, adipokines, inflammatory mediators, and emerging metabolomic, lipidomic, and microRNA signatures. These markers include myostatin, irisin, and the leptin-to-adiponectin ratio.

Sponsored content

Framework for Early Detection

Integrating these phenotypic and circulating biomarkers offers a potential framework for precise risk characterization. This approach aims to facilitate earlier, individualized identification of SO. The framework is conceptual and requires standardization and prospective validation to ensure reliable results. This research highlights the importance of considering muscle health alongside fat mass when assessing an individual’s risk profile. The integration of multiple biomarkers represents a promising strategy for detecting SO before functional impairment occurs. In the context of pharmacological weight loss interventions, preserving muscle mass is becoming increasingly important. Further research is needed to establish standardized cut-offs for these molecular markers and to validate the proposed framework through prospective studies.

Original Scientific Source
Frontiers in nutrition
View Original Source
Medical Disclaimer All calculations, recommendations, and interpretations provided by this tool are for informational and educational purposes only. They do not substitute professional medical advice, diagnosis, or treatment. Always consult your physician regarding any health concerns.

Recommended Medical News

All news →
Genetic axes of hand and shoulder soft-tissue disease and their divergent responses to adiposity and incretin therapy: a cross-biobank genomic and randomised trial study
overweight-obesity

Genetic axes of hand and shoulder soft-tissue disease and their divergent responses to adiposity and incretin therapy: a cross-biobank genomic and randomised trial study

Summary Background Hand and shoulder soft-tissue disorders cluster in people with obesity and diabetes, now widely treated with incretin receptor agonists. Whether these disorders share genetic causes, and whether pharmacological weight loss relieves or provokes them, is unknown. Methods We analysed genome-wide data...

28. 10. 2026 Read article →
The interpretation of body-composition metrics in obesity
overweight-obesity

The interpretation of body-composition metrics in obesity

Modern obesity care is increasingly therapeutic, longitudinal, and outcome-oriented, yet clinical assessment often remains centered on total body weight and BMI. Although BMI remains useful for screening and population-level risk stratification, it cannot characterize the biological heterogeneity of obesity or the...

26. 10. 2026 Read article →
Efficacy and safety of orforglipron in adults with body mass index of 27 to less than 30 kg/m 2 and adiposity-related complications: A post hoc analysis of the ATTAIN-1 trial
overweight-obesity

Efficacy and safety of orforglipron in adults with body mass index of 27 to less than 30 kg/m 2 and adiposity-related complications: A post hoc analysis of the ATTAIN-1 trial

Background Orforglipron, an oral small-molecule glucagon-like peptide-1 receptor agonist, improved body weight and cardiometabolic parameters in the phase 3 ATTAIN-1 trial, but its efficacy and safety in adults with body mass index (BMI) of ≥27 to 2 and adiposity-related complications have not been characterized....

14. 10. 2026 Read article →
Advertisement